Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity

Abstract

A substantial proportion of the worldwide liver cancer incidence is associated with chronic hepatitis B virus (HBV) infection. The therapeutic management of HBV infections is still problematic and novel antiviral strategies are urgently required. Using the peptide aptamer screening system, we aimed to isolate new molecules, which can block viral replication by interfering with capsid formation. Eight peptide aptamers were isolated from a randomized expression library, which specifically bound to the HBV core protein under intracellular conditions. One of them, named C1-1, efficiently inhibited viral capsid formation and, consequently, HBV replication and virion production. Hence, C1-1 is a novel model compound for inhibiting HBV replication by blocking capsid formation and provides a new basis for the development of therapeutic molecules with specific antiviral potential against HBV infections.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD . 1998 Hepatology 27: 1670–1677

  • Beasley RP . 1988 Cancer 61: 1942–1956

  • Blum HE, Zhang Z-S, Galun E, von Weizsäcker F, Garner B, Liang TJ, Wands JR . 1992 J. Virol. 66: 1223–1227

  • Böttcher B, Tsuji N, Takahashi H, Dyson MR, Zhao S, Crowther RA, Murray K . 1998 EMBO J. 23: 6839–6845

  • Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F . 2000 Proc. Natl. Acad. Sci. USA 97: 6693–6697

  • Butz K, Shahabeddin L, Geisen C, Spitkovsky D, Ullmann A, Hoppe-Seyler F . 1995 Oncogene 10: 927–936

  • Calvert J, Summers J . 1994 J. Virol. 68: 2084–2090

  • Chang CM, Jeng KS, Hu CP, Lo SJ, Su TS, Ting L-P, Chu C-K, Han S, Pfaff E, Salfeld J, Schaller H . 1987 EMBO J. 6: 675–680

  • Chevray PM, Nathans D . 1992 Proc. Natl. Acad. Sci. USA 89: 5789–5793

  • Christianson TW, Sikorski RS, Dante M, Shero JH, Hieter P . 1992 Gene 110: 119–122

  • Cohen BA, Colas P, Brent R . 1998 Proc. Natl. Acad. Sci. USA 95: 14272–14277

  • Colas P . 2000 Curr. Opin. Chem. Biol. 4: 54–59

  • Colas P, Cohen B, Jessen T, Grishina I, McCoy J, Brent R . 1996 Nature 380: 548–550

  • Conway JF, Cheng N, Zlotnick A, Wingfield TP, Stahl SJ, Steven AC . 1997 Nature 386: 91–94

  • Crowther RA, Kiselev NA, Böttcher B, Berriman JA, Borisova GP, Ose V, Pumpens P . 1994 Cell 77: 943–950

  • Cunningham BC, Wells JA . 1997 Curr. Opin. Struct. Biol. 7: 457–462

  • Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA . 1999 N. Engl. J. Med. 341: 1256–1263

  • Dyson MR, Murray K . 1995 Proc. Natl. Acad. Sci. USA 92: 2194–2198

  • Elliott G, O'Hare P . 1999 Gene Therapy 6: 149–151

  • Fabbrizio E, Le Cam L, Polanowska J, Kaczorek M, Lamb N, Brent R, Sardet C . 1999 Oncogene 18: 4357–4363

  • Ganem D . 1996 Virology Fields BN, Knipe DM, Howley PM (eds) Lippincott-Raven: Philadelphia pp. 2703–2737

    Google Scholar 

  • Harlow E, Lane D . 1999 Using Antibodies. A Laboratory Manual Harlow E and Lane D (eds) Cold Spring Harbor Laboratory Press: Cold Spring Harbor pp. 221–265

    Google Scholar 

  • Hoppe-Seyler F, Butz K . 2000 J. Mol. Med. 78: 426–430

  • Kolonin MG, Finley RL . 1998 Proc. Natl. Acad. Sci. USA 95: 14266–14271

  • König S, Beterams G, Nassal M . 1998 J Virol. 72: 4997–5005

  • Ladner RC . 1995 Trends Biotech. 13: 426–430

  • Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent RC, Barber J, Stephenson SL, Gray DF . 1998 N. Engl. J. Med. 333: 61–68

  • Lamberts C, Nassal M, Velhagen I, Zentgraf H, Schröder CH . 1993 J. Virol. 67: 3756–3762

  • Leung D, Abbenante G, Fairlie DP . 2000 J. Med. Chem. 43: 305–340

  • Pisani P, Parkin DM, Ferlay J . 1993 Int. J. Cancer 54: 594–606

  • Pisani P, Parkin DM, Munoz N, Ferlay J . 1997 Cancer Epid. Biomark. Prevent. 6: 387–400

  • Robinson WS . 1994 Annu. Rev. Med. 45: 297–323

  • Roingeard P, Su SL, Sureau C, Freschlin M, Arbeille B, Essex M, Romet-Lemonne JL . 1990 Hepatology 11: 277–285

  • Scaglioni P, Melegari M, Takahashi M, Chowdhury JR, Wands J . 1996 Hepatology 24: 1010–1017

  • Scaglioni PP, Melegari M, Wands J . 1994 Virology 205: 112–120

  • Seifer M, Standring DN . 1995 Intervirology 38: 47–62

  • Summers J, Mason B . 1982 Cell 29: 403–415

  • Summers J, Smith PM, Horwich AL . 1990 J. Virol. 64: 2819–2824

  • Sureau C, Romet-Lemonne JL, Mullins JI, Essex M . 1986 Cell 7: 37–47

  • Tuttleman JS, Pourcel C, Summers J . 1986 Cell 47: 451–460

  • Vidal M, Brachmann RK, Fattaey A, Harlow E, Boeke JD . 1996 Proc. Natl. Acad. Sci. USA 93: 10315–10320

  • Visintin M, Tse E, Axelson H, Rabbits TH, Cattaneo A . 1999 Proc. Natl. Acad. Sci. USA 96: 11723–11728

  • von Weizsäcker F, Köck J, Wieland S, Offensperger W-B, Blum HE . 1998 Hepatology 30: 308–315

  • von Weizsäcker F, Wieland S, Blum HE . 1996 Hepatology 24: 294–299

  • von Weizsäcker F, Wieland S, Köck J, Offensperger W-B, Offensperger S, Moradpour D, Blum HE . 1997 Hepatology 26: 251–255

  • Wright TL, Lau YN . 1993 Lancet 342: 1340–1344

  • Wu T-T, Coates L, Aldrich CE, Summers J, Mason B . 1990 Virology 175: 255–161

  • Wynne SA, Crowther RA, Leslie AGW . 1999 Mol Cell 3: 771–780

  • Yaginuma K, Shirakata Y, Kobayashi M, Koike K . 1987 Proc. Natl. Acad. Sci. USA 84: 2678–2682

  • Zhou S, Standring DN . 1992 Proc. Natl. Acad. Sci. USA 89: 10046–10050

Download references

Acknowledgements

We thank H zur Hausen for continuous support. We further thank B Ehret for excellent technical assistance, C Kuhn, H Schaller, S Urban, and H Zentgraf for biological materials, and U Ackermann for photographic work. We also thank S Karpen, S Urban and E Tomai for helpful comments on the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Felix Hoppe-Seyler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Butz, K., Denk, C., Fitscher, B. et al. Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene 20, 6579–6586 (2001). https://doi.org/10.1038/sj.onc.1204805

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204805

Keywords

Search

Quick links